[EN] FATTY ACID ANTICANCER DERIVATIVES AND THEIR USES<br/>[FR] DÉRIVÉS D'ACIDES GRAS ANTI-CANCÉREUX ET LEURS UTILISATIONS
申请人:CATABASIS PHARMACEUTICALS INC
公开号:WO2014204856A1
公开(公告)日:2014-12-24
The invention relates to fatty acid anticancer derivatives; compositions comprising an effective amount of a fatty acid anticancer derivative; and methods for treating or preventing cancer comprising the administration of an effective amount of a fatty acid anticancer derivative.
The invention provides 4-substituted aryl-5-hydroxyisoquinolinone derivatives and their pharmacologically acceptable addition salts with excellent inhibitory effect on poly (ADP-ribose) synthetase.
4-Substituted aryl-5-hydroxyisoquinolinone derivatives, represented by a general formula (1)
and their pharmacologically acceptable addition salts.
The invention provides 4-substituted aryl-5-hydroxyisoquinolinone derivatives and their pharmacologically acceptable addition salts with excellent inhibitory effect on poly (ADP-ribose) synthetase.
4-Substituted aryl-5-hydroxyisoquinolinone derivatives, represented by a general formula (1)
and their pharmacologically acceptable addition salts.
AGENT FOR REDUCTION OF BLEEDING IN CEREBROVASCULAR DISORDER
申请人:ONO PHARMACEUTICAL CO., LTD.
公开号:EP1908481A1
公开(公告)日:2008-04-09
The present invention relates to a hemorrhage reducing agent in cerebrovascular disorder containing a poly (ADP- ribose) polymerase inhibitor (PARP inhibitor). The PARP inhibitor provides an inhibitory effect of vascular endothelial cell disorder so that it may reduce hemorrhage in cerebrovascular disorder. In addition, the PARP inhibitor inhibits the hemorrhage that is concerned about in thrombolytic agent use by using together with a thrombolytic agent, and an effect of extending therapeutic time window of a thrombolytic agent may be further expected. Furthermore, the PARP inhibitor can be a safe hemorrhage reducing agent with fewer side effects because it does not affect the blood coagulation system and the fibrinolytic system.